BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
-2.74 (-3.85%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 66.20 - 71.58
52 week 66.20 - 151.75
Open 70.75
Vol / Avg. 2.24M/1.82M
Mkt cap 10.61B
P/E     -
Div/yield     -
EPS -1.98
Shares 161.25M
Beta 1.01
Inst. own 107%
Feb 25, 2016
Q4 2015 Biomarin Pharmaceutical Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 25, 2016
Q4 2015 Biomarin Pharmaceutical Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 11, 2016
Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference - Webcast
Nov 11, 2015
Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -43.53% -17.84%
Operating margin -39.19% -12.46%
EBITD margin - -12.36%
Return on average assets -10.03% -5.66%
Return on average equity -15.69% -9.34%
Employees 1,681 -
CDP Score - -


105 Digital Dr
NOVATO, CA 94949-8703
United States - Map
+1-415-5066700 (Phone)
+1-415-3827889 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Officers and directors

Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 60
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Executive Vice President and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller, Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Richard A. Meier Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Michael G. Grey Independent Director
Age: 62
Bio & Compensation  - Reuters